Capital News

Infliximab Biosimilar Insight: Assessment of active pipeline assets segmented by stage, product type, route of administration and molecule type

 Breaking News
  • No posts were found

Infliximab Biosimilar Insight: Assessment of active pipeline assets segmented by stage, product type, route of administration and molecule type

June 02
21:36 2021
Infliximab Biosimilar Insight: Assessment of active pipeline assets segmented by stage, product type, route of administration and molecule type

Infliximab Biosimilar Insight
The “Infliximab– Biosimilar Insight, 2021” report from DelveInsight gives detailed information on 35+ companies and 45+ marketed and pipeline therapies in the Infliximab Biosimilars market. It also includes clinical and nonclinical stage products, as well as commercial and pipeline medication profiles.

The “Infliximab– Biosimilar Insight, 2021” report from DelveInsight gives detailed information on 35+ companies and 45+ marketed and pipeline therapies in the Infliximab Biosimilars market. It also includes clinical and nonclinical stage products, as well as commercial and pipeline medication profiles.

Some Key Highlights from the Infliximab Biosimilar Insight Report

  • There are currently 35+ major companies including Janssen Biotech,Celltrion, Pfizer, Genor Biopharma, Samsung Bioepis, Prestige BioPharma and Sandoz working in the Infliximab Biosimilar market landscape.

  • Merck launched a biosimilar of Remicade (infliximab), a blockbuster immune-mediated inflammatory diseases medication, in the United States in July 2017, while Janssen Biotech markets the drug domestically.

  • Inflectra (infliximab-dyyb) (Celltrion/Pfizer) was approved by the US Food and Drug Administration in April 2016 for all qualifying indications of the reference product, Remicade® (Infliximab). This is the second biosimilar approved by the FDA.

  • GB 242 (Genor Biopharma), Ixifi (Pfizer),  SB2 (Samsung Bioepis), PBP 1505 (Prestige BioPharma), Zessly (Sandoz), others are among the Infliximab Biosimilar emerging drugs.

Learn more by requesting sample @ Infliximab Biosimilar Insight

Infliximab (Remicade): Product Overview

Infliximab is a chimeric monoclonal antibody that is used to treat a variety of autoimmune diseases. It is offered under the brand names Remicade and others. 

Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease are among the conditions that fall under this category. 

Infliximab Biosimilar Marketed Drug Product Profile

Inflectra: Celltrion/Pfizer

Inflectra is a biosimilar to Remicade (Infliximab), a reference biologic. The therapy has been approved for the treatment of adults and children (ages six and above) with moderate to severe active Crohn’s disease who have had a poor response to conventional therapy, adults with moderate to severe active ulcerative colitis who have not responded to conventional therapy; moderate to severe active rheumatoid arthritis in combination with methotrexate; active ankylosing spondylitis; active psoriatic arthritis; and chronic severe plaque psoriasis.

Infliximab Biosimilar Emerging Drug Product Profile

GB 242: Genor Biopharma

Product Description

Genor Biopharma (a Walvax Biotechnology affiliate) is working on a biosimilar of Infliximab called GB 242 for the treatment of autoimmune disorders and rheumatoid arthritis. For the treatment of Rheumatoid Arthritis, the drug is now in phase III development.

Research and Development in the GB 242 Biosimilar Landscape

Phase III

NCT04178850: A Randomized, Double-blind, Multi-center Phase III Comparative Study to Evaluate the Efficacy and Safety of Recombinant Human-mouse Chimeric Anti-TNF-alpha Monoclonal Antibody for Injection was launched by Genor Biopharma in October 2017. The proportion of individuals who attained ACR20 at week 30 in the two groups is compared in this study.

For more insights visit Infliximab Biosimilar Marketed and Emerging Drugs

Infliximab Biosimilar Major Players

  • Janssen Biotech

  • Celltrion

  • Pfizer

  • Genor Biopharma

  • Samsung Bioepis

  • Prestige BioPharma

  • Sandoz

Infliximab Biosimilar Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

Scope of the Report

Coverage: Global

Infliximab Biosimilar Key Players: Janssen Biotech, Celltrion/Pfizer and Genor Biopharma, among others

Table of Contents

1.

Key Insights

2.

Infliximab Biosimilars: Snapshot

3.

Executive Summary

4.

Regulatory Outlook For Biosimilars

5.

Infliximab (Reference Product:  Remicade)

6.

Infliximab Biosimilar Research and Development

7.

Remicade Biosimilar:  Emerging Opportunities

8.

Infliximab: Biosimilars Assessment

9.

Infliximab Biosimilars Profiles: By Company

10.

Infliximab Biosimilars: Comparative Landscape: By Company

11.

Infliximab Biosimilars: Competitive Landscape

12.

Infliximab Biosimilars Market Drivers

13.

Infliximab Biosimilars Market Barriers

14.

Infliximab Biosimilars SWOT Analysis

15.

Appendix

16.

Bibliography

17.

DelveInsight Capabilities

18.

Disclaimer

19.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare and Biotech Blog Posts

Related Reports

Etanercept Biosimilar Insights

Get comprehensive analysis of Etanercept pipeline drugs and key companies including Sandoz, Samsung Bioepis, Reliance Life Sciences, Probiomed, Pfizer, Merck, Cipla, Biocon, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance.  

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/


Warning: count(): Parameter must be an array or an object that implements Countable in /home/capitalnews/public_html/wp-content/themes/legatus-theme/includes/single/post-tags.php on line 5
Share

Recent Posts

China-hifi-Audio Presents the Best Amplifier Award Tube Amplifier Willsenton R8 Known Worldwide for Generating Quality, Smooth, And Clearer Sounds

Read Full Article

Categories